t(2;5)(p23;q35) NPM1/ALK
2001-08-01 Jean-Loup Huret   Affiliation1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
Translocations involving 2p23 are found in more than half cases of anaplasic large cell lymphoma (ALCL), a high grade non Hodgkin lymphoma (NHL). They involve ALK, and are therefore called ALK+ ALCL. The t(2;5) is the far most frequent 2p23 translocation in ALK+ ALCL.
Phenotype stem cell origin
T-cell in 80% (or 100%?), or null-cell type; B-cell cases, if they exist, would represent cases of large B-cell lymphomas; CD30+; present with some overlapping features with Hodgkins disease: CD30 positivity and Reed-Sternberg like cells, but the t(2;5) is not found in Hodgkins disease (it has long been debated)
Epidemiology
10% of NHL; found in children and young adults; median around 16 yrs)
Clinics
involve lymph nodes and extra nodal sites such as lungs and gastro intestinal tract
Cytology
t(2;5) is found in about 30-50% of anaplastic large cell NHL (also called ALCL); it was thought previously that the t(2;5) could be found in diffuse large cell NHL or immunoblastic NHL; however, cases may easily be misdiagnosed, as the malignant cells display a pleomorphic appearance
Prognosis
although t(2;5) is found in aggressive high grade tumours, a 80% five yr survival seems to be associated with this anomaly
Cytogenetics
Additional anomalies
sole anomaly in less than 20% of cases; often part of a complex karyotype, with various structural and/or numerical anomalies; recurrent numerical anomalies are: +7, found in 20% of cases, +9, and +X, in 5 to 10% of cases.
Variants
closely related anomalies, also found in anaplastic large cell lymphoma, are: t(X;2)(q11;p23), t(1;2)(q25;p23), inv(2)(p23q35), t(2;3)(p23;q21), t(2;17)(p23;q23), t(2;19)(p23; p13.1) and t(2;22)(p23;q11.2). They all involve ALK in 2p23.
Genes Involved and Proteins
Gene name
ALK (anaplastic lymphoma receptor tyrosine kinase)
Location
2p23.2
Protein description
after glycosylation, produces a glycoprotein; membrane associated tyrosine kinase receptor
Gene name
NPM1 (nucleophosmin)
Location
5q35.1
Protein description
nuclear localisation; RNA binding nucleolar phosphoprotein involved in preribosomal assembly
Result of the Chromosomal Anomaly
Description
5 NPM-3 ALK on der(5)
Transcript
2.4 kb
Description
80 kDa; 680 amino acids; the 116 N-term aminoacids from NPM are fused to the 563 C-term aminoacids of ALK (i.e. composed of the oligomerization domain and the metal binding site of NPM1, and the entire cytoplasmic portion of ALK); no apparent expression of the ALK/NPM1 counterpart. Characteristic localisation both in the cytoplasm and in the nucleus, due to heterooligomerization of NPM-ALK and normal NPM whereas the normal NPM protein is confined to the nucleus; constitutive activation of the catalytic domain of ALK.
Expression localisation
localisation: both in the cytoplasm and in the nucleus (nucleoplasm and nucleolus)
Oncogenesis
via the kinase function activated by oligomerization of NPM-ALK mediated by the NPM part
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 32922661 | 2020 | The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL). | 102 |
| 32573700 | 2020 | IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. | 78 |
| 35807279 | 2022 | Synthesis of 4,5-Dihydro-1H-[1,2]dithiolo[3,4-c]quinoline-1-thione Derivatives and Their Application as Protein Kinase Inhibitors. | 67 |
| 35277956 | 2023 | Reassessing pharmacogenomic cell sensitivity with multilevel statistical models. | 62 |
| 37773266 | 2023 | Chimeric kinase ALK induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function. | 60 |
| 31804622 | 2020 | The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. | 55 |
| 28659337 | 2017 | Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene. | 48 |
| 34242968 | 2021 | Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. | 47 |
| 33572634 | 2021 | How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report. | 45 |
| 23568838 | 2013 | Cancer translocations in human cells induced by zinc finger and TALE nucleases. | 43 |
| 33514657 | 2021 | Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells. | 41 |
| 30240643 | 2018 | Chromosomal Translocation Formation Is Sufficient to Produce Fusion Circular RNAs Specific to Patient Tumor Cells. | 38 |
| 31189527 | 2019 | CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK(+) lymphoma after transplantation. | 33 |
| 36114670 | 2023 | Targeted genomic translocations and inversions generated using a paired prime editing strategy. | 30 |
| 25602801 | 2015 | Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. | 30 |
| 20207848 | 2010 | ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. | 26 |
| 30696805 | 2019 | CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas. | 15 |
| 26187744 | 2015 | Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease. | 8 |
| 25961701 | 2015 | The origins of ALK translocations. | 0 |
| 19545284 | 2009 | Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation. | 0 |
| 38279625 | 2024 | Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group. | 0 |
| 35460414 | 2022 | Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK Positive. | 0 |
| 38266918 | 2024 | Molecular Screening in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: Anaplastic Lymphoma Kinase Analysis, Next-Generation Sequencing Fusion Gene Detection, and T-Cell Receptor Immunoprofiling. | 0 |
| 17922009 | 2007 | STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. | 0 |
| 39774774 | 2025 | Endogenous CD4 T cells that recognize ALK and the NPM1::ALK fusion protein can be expanded from human peripheral blood. | 0 |
| 39237383 | 2024 | ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases. | 0 |
| 33246076 | 2021 | Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR. | 0 |
| 22912387 | 2012 | Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. | 0 |
| 32412717 | 2020 | Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma. | 0 |
| 23999969 | 2013 | Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. | 0 |
| 39784678 | 2025 | A rare cause of intestinal obstruction: jejunal ALK positive anaplastic large-cell lymphoma. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 9121481 | 1997 | Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. | Bischof D et al |
| 9078287 | 1997 | Cytogenetics of lymphomas: a brief review of its theoretical and practical significance. | Donner LR et al |
| 2156548 | 1990 | CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. | Mason DY et al |
| 8122112 | 1994 | Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. | Morris SW et al |
| 11380391 | 2001 | Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. | Morris SW et al |
| 11090048 | 2000 | CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. | Stein H et al |
| 7662979 | 1995 | Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. | Wellmann A et al |
Summary
Fusion gene
NPM1/ALK NPM1 (5q35.1) ALK (2p23.2) COF 198 199 200 201 420 448 449 450 451 452 453 454 455 456 457 458|NPM1/ALK NPM1 (5q35.1) ALK (2p23.2) M ins(5;2)(q35;p23p23) t(2;5)(p23;q35)|NPM1/ALK NPM1 (5q35.1) ALK (2p23.2) TIC

t(2;5)(p23;q35) NPM1/ALK G-banding (left) [note tetraploid cells (second and third row)] and R- banding (right); - Courtesy Jean-Luc Lai and Alain Vanderhaegen; center: G-banding - Courtesy Adriana Zamecnikova. Fluorescence in situ hybridization (FISH) with Vysis ALK Break Apart probe (Abbott Molecular, US) showing rearrangement of the gene on metaphases with t(2;5)(p23;q35) (green signal on der(2) and red signal on der(5) chromosome). - Courtesy Adriana Zamecnikova.
Citation
Jean-Loup Huret
t(2;5)(p23;q35) NPM1/ALK
Atlas Genet Cytogenet Oncol Haematol. 2001-08-01
Online version: http://atlasgeneticsoncology.org/haematological/2000
Historical Card
1997-12-01 t(2;5)(p23;q35) NPM1/ALK by Jean-Loup Huret  Affiliation
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
1997-08-01 t(2;5)(p23;q35) NPM1/ALK by Jean-Loup Huret  Affiliation
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
